Mark Rolfe
About Mark Rolfe
Mark Rolfe is the Senior Vice President at Bristol-Myers Squibb with over 30 years of experience in cancer drug discovery and development.
Current Role at Bristol-Myers Squibb
Mark Rolfe currently serves as the Senior Vice President at Bristol-Myers Squibb. Since November 2019, he has played a pivotal role in overseeing the development and implementation of Risk Evaluation and Mitigation Strategies (REMS) for certain medications. Additionally, he ensures that investigational medicines are accessible to patients through Pre-Approval Access programs. As part of his responsibilities, Mark works closely with physicians to assess individual patient cases for access to investigational medicines, emphasizing patient safety and public health.
Previous Experience at Celgene
Prior to his current role, Mark Rolfe was the Corporate Vice President at Celgene from 2017 to 2019. During his tenure at Celgene, he contributed significantly to various aspects of corporate strategy and development, particularly in the areas of cancer drug discovery and development. His role involved working in both San Diego and San Francisco, where he built strong relationships within the biotech community.
Leadership at Cleave Biosciences
Mark Rolfe served as the President and Chief Scientific Officer at Cleave Biosciences from 2011 to 2017. During his six-year tenure, he was instrumental in leading the company's scientific and strategic direction. His work focused on advancing the development of small molecule and antibody-based therapeutics, building a robust pipeline of potential treatments. Under his leadership, Cleave Biosciences made significant strides in cancer drug discovery and development.
Tenure at Millennium Pharmaceuticals
Mark Rolfe worked as the Vice President of Discovery Oncology at Millennium Pharmaceuticals from 1999 to 2009. In this role, he led efforts in discovering new cancer therapies and was involved in various projects that contributed to the advancement of oncology treatments. His decade-long tenure at Millennium Pharmaceuticals was marked by significant achievements in the field of oncology and drug discovery.
Educational Background and Early Career
Mark Rolfe holds a Ph.D. in Molecular Genetics from the Medical Research Council, National Institute for Medical Research, where he studied from 1982 to 1985. He also achieved an MA and BA in Biochemistry from the University of Oxford, studying from 1978 to 1982. His post-doctoral research at the Imperial Cancer Research Fund and his visiting fellowship at Columbia University Vagelos College of Physicians and Surgeons laid a solid foundation for his career in the biotech industry. With over 30 years of experience, Mark has specialized in cancer drug resistance and DNA damage response, contributing significantly to the field of biopharmaceutical research and development.